SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

“Hmmm” is a community meme token on the Solana network, launched on July 22, 2024, through Pumpfun. It’s a derivative of Pepe the Frog but has evolved into its own distinct meme with a unique identity. The token embraces the humor and intrigue of internet culture, playing on the idea of curiosity and speculation. “Hmmm” captures a playful approach to the world of meme tokens, designed to engage a community driven by fun and the whimsical side of crypto. Hmmm, maybe this’ll send.

hmmm

HMMM crypto is trending as community members highlight its association with Phantom Wallet. Conversations mention potential for significant gains and early hype around the token. Some users are pointing to a possible breakout while others urge caution, and many are sharing links related to the token.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending as community members discuss its potential in the expanding play-to-earn and virtual world sectors, focusing on its technology that bridges blockchain with gaming. Conversations highlight the growing community, new exchange listings, and its potential within the AI and blockchain space. Some traders are also taking profits from other tokens and moving them into Virtual Protocol.

Trump For President

TRUMP CRYPTO is trending amid discussions around Donald Trump's political activities and their potential impact on the crypto market, with community members debating the legitimacy and future prospects of Trump-related digital assets. Some traders are weighing the token's potential, while others voice concerns about its performance and broader implications. The conversation extends to Trump's stance on trade, his relationship with other political figures, and the performance of other Trump-related assets.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The DIA is trending amid renewed trade tensions between the U.S. and China, sparked by tariff threats and export restrictions. Community discussions revolve around the potential economic impact and whether a meeting between leaders can de-escalate the situation. Some traders are anticipating market volatility and adjusting their positions accordingly, while others remain optimistic about a resolution.

Plasma is the layer 1 blockchain building the stablecoin infrastructure for a new global financial system.   It is purpose-built for global stablecoin payments, offering zero-fee USD₮ transfers and custom gas tokens to help realise the stablecoin promise of permissionless access to financial services for everyone, everywhere.   Plasma’s global payments coverage and inbound suite of products position it as the native chain for stablecoin payments.

Plasma

Plasma (XPL) is trending amid discussions about its potential, with some community members pointing to a listing on a Chinese exchange and a Federal Reserve stablecoin conference as possible catalysts. There's also chatter about a partnership with Alchemy Pay to facilitate fiat on-ramps, while others express concerns about recent price drops and potential market manipulation. Overall, the community is weighing both bullish developments and bearish price action.

Citizens Financial Group, Inc. engages in the provision of commercial banking services. It operates through the Consumer Banking and Commercial Banking segments. The Consumer Banking segment includes deposit products, mortgage and home equity lending, student loans, auto financing, credit cards, business loans, and wealth management and investment services. The Commercial Banking segment offers lending and leasing, trade financing, deposit and treasury management, foreign exchange and interest rate risk management, corporate finance and debt, and equity capital markets. The company was founded in 1828 and is headquartered in Providence, RI.

Citizens Financial Group Inc

Citizens Financial Group is trending as analysts adjust their ratings and target prices following Q3 earnings and a dividend increase, with community members discussing potential entry points for call options. Positive EPS and revenue figures are fueling FOMO among some investors, while others are wary of broader market volatility impacting the regional bank. Morgan Stanley recently upgraded $CFG to Overweight, while other firms have adjusted price targets, contributing to the ongoing conversation.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Inu is trending as the community rallies around the project, anticipating a significant reversal and potential breakout. Dubbed the "Wolfpack," the community expresses strong conviction and diamond-handed holding, with many believing $SAILANA has the potential for substantial gains. Talk centers around the community's strength and upcoming news, with some comparing it to early Shiba Inu.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amid discussions around potential tariffs on Canada following a Reagan trade ad controversy, sparking debate about trade wars and their impact. Community members are also focused on Marjorie Taylor Greene's criticism of Republican leadership regarding the government shutdown. Speculation abounds regarding Trump's crypto holdings and their potential impact on the stock.

Trulieve Cannabis Corp. engages in the provision of medical cannabis products and services. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Quincy, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve Cannabis ($TCNNF) is trending as discussions swirl around potential federal cannabis rescheduling following comments from a prominent political figure. Community members are weighing the implications of rescheduling, including tax benefits and institutional investment, while also considering potential impacts from state-level legalization efforts. Some traders believe now is the time to accumulate shares in anticipation of significant sector growth.

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Biogen Inc

Biogen ($BIIB) is trending due to a mix of factors, including recent developments around its Alzheimer's drug, Leqembi, and speculation about potential acquisitions. Community discussions revolve around the company's strategy, pipeline, and valuation amid shifting market dynamics, with some analysts adjusting price targets and ratings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Harrow (HROW) announced on Friday that it has entered into an agreement to acquire privately held Melt Pharmaceuticals for an undisclosed price.While Harrow is a provider of ophthalmic disease management solutions, Melt Pharmaceuticals is focused on developing non-opioid therapies for sedation during medical procedures. Melt was spun out of Harrow in January 2019.The acquisition will <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.harrow.com/news-releases/news-release-details/harrow-acquire-melt-pharmaceuticals">include</a> Melt’s lead investigational therapy, MELT-300, a sublingually delivered formulation of a fixed dose of Midazolam (3mg) and Ketamine (50mg) designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration.Shares of Harrow jumped 4% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HROW">HROW stock</a> stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.MELT-300 was found to be statistically superior to both sublingual Midazolam alone and placebo in providing successful procedural sedation in a late-stage study. A recently completed cardiac safety study also indicated that MELT-300 did not alter normal heart rhythm, supporting the therapy’s safety profile. Harrow now plans to submit a new drug application to the U.S. Food and Drug Administration for the sedative in 2027, and is eyeing a commercial launch in the U.S. in 2028.If the FDA approves MELT-300, the company intends to discontinue the MKO Melt sedation product, marketed through its ImprimisRx subsidiary, for cataract surgeries. The company also sees potential for MELT-300 to be used in other procedures, including claustrophobia during MRIs, sedation for colonoscopies, dental procedures, gastroenterology procedures, and other interventions.The closing of the merger transaction, however, is subject to customary closing conditions, including approval by Melt shareholders, Harrow added.HROW stock is up 43% this year and by about 9% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/costco-draws-mixed-reactions-from-wall-street-despite-q4-beat-here-is-why/chDVjZGR3eX">Costco Draws Mixed Reactions From Wall Street Despite Q4 Beat: Here’s Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Harrow To Acquire Sedation Solutions Developer Melt Pharmaceuticals – More Details Inside

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration. 

Equity

The acquisition will include Melt’s lead investigational therapy, MELT-300, designed to provide rapid, predictable sedation and analgesia without the need for intravenous administration. 


Surging Earnings Estimates Signal Upside for Harrow (HROW) Stock

Harrow (HROW) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Best Momentum Stock to Buy for August 15th

ECG, NVT and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 15, 2025.

Wall Street Analysts Think Harrow (HROW) Could Surge 53.24%: Read This Before Placing a Bet

The mean of analysts' price targets for Harrow (HROW) points to a 53.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar?

Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Are Options Traders Betting on a Big Move in Harrow Stock?

Investors need to pay close attention to HROW stock based on the movements in the options market lately.

Harrow Health, Inc reported a wider first-quarter loss on Thursday but reaffirmed its full-year revenue outlook, prompting a pickup in retail trading activity.The eyecare pharmaceutical firm posted a net loss of $17.8 million, or 38 cents per share, compared with a loss of $13.6 million, or 28 cents per share, a year earlier.&nbsp;Harrow shares closed at $23.59, down 4.07% on Thursday, and dropped further in after-hours trading, falling $2.49, or 10.56% to $21.10.Revenue rose 38% year-over-year to $47.8 million, driven by increased uptake of Vevye, a prescription ophthalmic drug for dry eye disease.&nbsp;Vevye recorded $21.5 million in sales during the quarter.The company cited strong early demand from its new ‘Vevye Access for All’ program, launched in mid-March, with prescription volumes at specialty pharmacy PhilRx more than quadrupling.“Our Vevye refill rate continues to be buoyant, with the average covered patient receiving nine refills,” CEO Mark L. Baum said in a statement.Harrow reaffirmed its 2025 revenue target of over $280 million, slightly below analysts’ average estimate of $283.2 million.&nbsp;The company said it expects continued commercial momentum from its Iheezo and Triesence products, along with contributions from pending pipeline accounts.Management also reiterated its focus on strategic acquisitions to augment its U.S. commercial platform, calling out opportunities to add “high-quality ophthalmic pharmaceutical assets.”Sentiment on Stocktwits was described as "extremely bullish," amid a 2,200% surge in 24-hour message volume.One user expressed strong enthusiasm for the stock, commenting that there was "never a bad price to buy HROW" and that no matter the outcome, it's always "good news."&nbsp;<stembedurl>https://stocktwits.com/dpen1000/message/614022779</stembedurl>Another user highlighted the potential for VEVYE’s continued growth, noting that if it maintains its 35% quarter-over-quarter increase, the product alone could contribute $150 million in revenue for 2025.<stembedurl>https://stocktwits.com/HROW200/message/614007884</stembedurl>The stock has declined over 35% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stockbroker analyzing financial stock market with reflection on eyeglasses. Photo via Westend61 on Getty Images

Harrow Health Posts Larger Loss In Q1, But Retail Enthusiasm Grows As Dry Eye Disease Drug Drives Revenue

The company reported a net loss of $17.8 million, or 38 cents per share, compared to a loss of $13.6 million in the same period last year. Despite the wider loss, Harrow reiterated its 2025 revenue target of over $280 million.

Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates

Stock Index Futures Gain With All Eyes on Fed Rate Decision

March S&P 500 E-Mini futures (ESH25) are up +0.21%, and March Nasdaq 100 E-Mini futures (NQH25) are up +0.22% this morning, pointing to a slightly higher open on Wall Street as investors await the Federal Reserve’s policy decision and Chair Jerome Powell’s comments.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

HROW
Harrow Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest HROW News

HROWHarrow Health Inc